NOVARTIS logo.jpg
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
April 23, 2024 13:42 ET | Novartis Pharma AG
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic...
cmi_logo.png
[Latest] Global 3D Cell Culture Market Size/Share Worth USD 4.6 Billion by 2033 at a 11.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 18, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “3D Cell Culture Market Size, Trends and Insights By Product (Scaffolds Based 3d...
AIMLogo.jpg
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 18, 2024 08:45 ET | AIM ImmunoTech Inc.
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
IMG_5056
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects. 
April 17, 2024 10:15 ET | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most...
image1 (1).png
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
April 17, 2024 08:00 ET | Evaxion Biotech
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for one-year clinical efficacy readout in Q3...
The Leaderboard
The Interorganizational Network (ION) Rebrands as The Leaderboard
April 16, 2024 09:00 ET | The Leaderboard
The Leaderboard has become a national alliance of women's executive networks dedicated to supporting boardroom and corporate excellence.
Imugene Limited
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
April 15, 2024 16:09 ET | Imugene Limited
Imugene opened enrollment for its CF-33 (VAXINIA) expansion study in bile tract cancer (cholangiocarcinoma) patients.
RNAZ White background cropped.jpg
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 15, 2024 09:00 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Sheronda L. Carr, Vice President, Membership, SME
SME, Women in Manufacturing Expand Partnership & Co-Host Women of SMART Experience June 4
April 12, 2024 11:21 ET | SME
SME and WiM will host the Women of SMART Experience, co-located with the SME-and AMT-produced Smart Manufacturing Experience.
AIMLogo.jpg
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 11, 2024 11:00 ET | AIM ImmunoTech Inc.
OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...